Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe. With two different allergy indications, Grass Pollen and Birch Pollen, these studies presented some unique challenges.
In our continued quest to reduce time and effort to bring medicines to market; Pharm-Olam is pleased to announce expansion into Israel. Pharm-Olam continues to look to increase its strategic footprint to offer our clients a greater choice to support their clinical trials. Incorporating Israel into your clinical trials offers you several benefits including:
HOUSTON, TX – Pharm-Olam International Ltd. a multi-national, full service provider of outsourced development services to the pharmaceutical and biotech industries, announced its successful expansion of clinical trial services into Kazakhstan.